Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


Carers' Corner

Beating ‘burnout’: nine ways to stay positive when caring for your partner

Caring for your partner can be challenging, but it doesn't have to be a bur

READ MORE
Work and Parkinson's

Episodes

Podcast: What’s it like managing your working life with Parkinson’s?

Our guests reflect on work life with Parkinson's

READ MORE
Lisa Holt

Interviews

Dog research could lead to detection of the cause of Parkinson’s

We are just a sniff away from finding the molecule for Parkinson’s diseas

READ MORE